These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 21232023)

  • 1. Meeting report from the 7th International Melanoma Congress, Sydney, November, 2010.
    Hersey P; Smalley KS; Weeraratna A; Bosenberg M; Zhang XD; Haass NK; Paton E; Mann G; Scolyer RA; Tüting T
    Pigment Cell Melanoma Res; 2011 Feb; 24(1):e1-15. PubMed ID: 21232023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Naevus lightening in melanoma patients under BRAF/MEK inhibitor combination therapy versus checkpoint immunotherapy: A histological and immunohistochemistry analysis.
    Zhao CY; Chou S; Liu RC; Fernandez-Peñas P
    Pigment Cell Melanoma Res; 2018 Mar; 31(2):341-344. PubMed ID: 29131505
    [No Abstract]   [Full Text] [Related]  

  • 3. The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma.
    Ramsdale R; Jorissen RN; Li FZ; Al-Obaidi S; Ward T; Sheppard KE; Bukczynska PE; Young RJ; Boyle SE; Shackleton M; Bollag G; Long GV; Tulchinsky E; Rizos H; Pearson RB; McArthur GA; Dhillon AS; Ferrao PT
    Sci Signal; 2015 Aug; 8(390):ra82. PubMed ID: 26286024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From targeted monotherapy to combined BRAF-MEK inhibitors and integrated genome analysis for melanoma treatment.
    Roukos DH; Papaloukas C; Tzaphlidou M
    Future Oncol; 2013 Jan; 9(1):5-8. PubMed ID: 23252557
    [No Abstract]   [Full Text] [Related]  

  • 5. Targeted Therapy for Melanoma.
    Wong DJ; Ribas A
    Cancer Treat Res; 2016; 167():251-62. PubMed ID: 26601866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MEK and RAF inhibitors for BRAF-mutated cancers.
    Belden S; Flaherty KT
    Expert Rev Mol Med; 2012 Oct; 14():e17. PubMed ID: 23058743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRAF signaling and targeted therapies in melanoma.
    Dhomen N; Marais R
    Hematol Oncol Clin North Am; 2009 Jun; 23(3):529-45, ix. PubMed ID: 19464601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [BRAF inhibitor and MEK inhibitor].
    Uhara H
    Gan To Kagaku Ryoho; 2015 Apr; 42(4):428-33. PubMed ID: 26020982
    [No Abstract]   [Full Text] [Related]  

  • 9. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
    Nakamura A; Arita T; Tsuchiya S; Donelan J; Chouitar J; Carideo E; Galvin K; Okaniwa M; Ishikawa T; Yoshida S
    Cancer Res; 2013 Dec; 73(23):7043-55. PubMed ID: 24121489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma.
    Queirolo P; Picasso V; Spagnolo F
    Cancer Treat Rev; 2015 Jun; 41(6):519-26. PubMed ID: 25944484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of BRAF-mutated metastatic melanoma].
    Boyles TB; Svane IM; Bastholt L; Schmidt H
    Ugeskr Laeger; 2016 Aug; 178(35):. PubMed ID: 27592869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug discovery: inhibitors that activate.
    Cichowski K; Jänne PA
    Nature; 2010 Mar; 464(7287):358-9. PubMed ID: 20237552
    [No Abstract]   [Full Text] [Related]  

  • 13. Immune Responses to BRAF-Targeted Therapy in Melanoma: Is Targeted Therapy Immunotherapy?
    Kelley MC
    Crit Rev Oncog; 2016; 21(1-2):83-91. PubMed ID: 27481005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new standard of care for metastatic melanoma?
    Sharma SP
    Lancet Oncol; 2015 Jan; 16(1):e8. PubMed ID: 25638559
    [No Abstract]   [Full Text] [Related]  

  • 15. Evidence for upregulation of Bim and the splicing factor SRp55 in melanoma cells from patients treated with selective BRAF inhibitors.
    Lai F; Jiang CC; Farrelly ML; Zhang XD; Hersey P
    Melanoma Res; 2012 Jun; 22(3):244-51. PubMed ID: 22516966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficient treatment of a metastatic melanoma patient with a combination of BRAF and MEK inhibitors based on circulating tumor DNA analysis: a case report.
    Quéreux G; Herbreteau G; Knol AC; Vallée A; Khammari A; Théoleyre S; Saint-Jean M; Dréno B; Denis MG
    BMC Res Notes; 2017 Jul; 10(1):320. PubMed ID: 28743309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Melanoma].
    Uhara H
    Gan To Kagaku Ryoho; 2016 Apr; 43(4):404-7. PubMed ID: 27220785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of BRAF-mutant melanoma: the role of vemurafenib and other therapies.
    Jang S; Atkins MB
    Clin Pharmacol Ther; 2014 Jan; 95(1):24-31. PubMed ID: 24080641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
    Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
    Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF inhibitors and melanoma.
    Flaherty KT
    Cancer J; 2011; 17(6):505-11. PubMed ID: 22157295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.